Literature DB >> 17917071

Monoclonal antibody mechanisms of action in cancer.

George J Weiner1.   

Abstract

Monoclonal antibodies (mAbs) are used extensively as treatment for cancer. A variety of mechanisms are thought to play important roles in mediating the observed anti-tumor effects of mAb. These include signaling mediated by cross-linking of surface antigen that leads to cell death, blocking an activation signal that is necessary for continued cell growth, antibody-dependent cellular cytotoxicity (ADCC), complement mediated cytotoxicity (CMC) and the ability of mAb to alter the cytokine milieu or enhance development of an active anti-tumor immune response. In this review the in vitro, animal model and clinical results supporting each of these varied mechanisms is summarized as is the potential for these mechanisms to interact with each other.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917071     DOI: 10.1007/s12026-007-0073-4

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  34 in total

1.  Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma.

Authors:  K S Brown; D J Levitt; M Shannon; B K Link
Journal:  Clin Lymphoma       Date:  2001-12

2.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

Authors:  R R French; H T Chan; A L Tutt; M J Glennie
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

Review 3.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

4.  CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells.

Authors:  Julie A Bowles; George J Weiner
Journal:  J Immunol Methods       Date:  2005-09       Impact factor: 2.303

5.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

6.  Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Mark Hansen; Andrew R Branagan; Sigitas Verselis; Christos Emmanouilides; Eva Kimby; Stanley R Frankel; Nikolaos Touroutoglou; Barry Turnbull; Kenneth C Anderson; David G Maloney; Edward A Fox
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

7.  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.

Authors:  D Shan; J A Ledbetter; O W Press
Journal:  Cancer Immunol Immunother       Date:  2000-03       Impact factor: 6.968

8.  CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

Authors:  Heidi H van Ojik; Lisette Bevaart; Christopher E Dahle; Annie Bakker; Marco J H Jansen; Martine J van Vugt; Jan G J van de Winkel; George J Weiner
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

Review 9.  Trastuzumab/chemotherapy combinations in metastatic breast cancer.

Authors:  Jennifer A Ligibel; Eric P Winer
Journal:  Semin Oncol       Date:  2002-06       Impact factor: 4.929

10.  Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells.

Authors:  Andrew P Mone; Peng Huang; Helene Pelicano; Carolyn M Cheney; Jennifer M Green; J Yun Tso; Amy J Johnson; Sara Jefferson; Thomas S Lin; John C Byrd
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

View more
  35 in total

Review 1.  Immunology at the University of Iowa.

Authors:  Gail A Bishop
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

2.  Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells.

Authors:  S L Fu; J Pierre; T A Smith-Norowitz; M Hagler; W Bowne; M R Pincus; C M Mueller; M E Zenilman; M H Bluth
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

Review 3.  Anti-GD2 antibody therapy for GD2-expressing tumors.

Authors:  Fariba Navid; Victor M Santana; Raymond C Barfield
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

4.  The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.

Authors:  T Magnes; T Melchardt; C Hufnagl; L Weiss; C Mittermair; D Neureiter; E Klieser; G Rinnerthaler; S Roesch; A Gaggl; R Greil; A Egle
Journal:  Pharmacogenomics J       Date:  2017-07-18       Impact factor: 3.550

5.  Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer.

Authors:  Maoyong Fu; Erin L Maresh; Robert A Soslow; Mohammad Alavi; Vei Mah; Qin Zhou; Alexia Iasonos; Lee Goodglick; Lynn K Gordon; Jonathan Braun; Madhuri Wadehra
Journal:  Clin Cancer Res       Date:  2010-08-01       Impact factor: 12.531

Review 6.  Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells.

Authors:  Fabrizio Marcucci; Matteo Bellone; Cristiano Rumio; Angelo Corti
Journal:  MAbs       Date:  2012-12-04       Impact factor: 5.857

Review 7.  Determining the optimal dose in the development of anticancer agents.

Authors:  Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij
Journal:  Nat Rev Clin Oncol       Date:  2014-03-25       Impact factor: 66.675

Review 8.  ING proteins as potential anticancer drug targets.

Authors:  M Unoki; K Kumamoto; C C Harris
Journal:  Curr Drug Targets       Date:  2009-05       Impact factor: 3.465

Review 9.  Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies.

Authors:  Steve C Lee; Andrés López-Albaitero; Robert L Ferris
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

10.  Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients.

Authors:  Raphaël Maréchal; Jef De Schutter; Nathalie Nagy; Pieter Demetter; Arnaud Lemmers; Jacques Devière; Isabelle Salmon; Sabine Tejpar; Jean-Luc Van Laethem
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.